Statistically significant lower risk is seen for mortality, hospitalization, and cases. 4 studies from 4 independent teams in 4 countries show significant improvements.
Meta analysis using the most serious outcome reported shows 40% [15‑58%] lower risk. Results are similar for Randomized Controlled Trials and peer-reviewed studies.
Currently there is limited data, with only 33 control events for the most serious outcome in trials to date.
2 RCTs with 664 patients have not reported results (up to 2 years late)1,2.
Montelukast has a boxed warning for neuropsychiatric side effects3.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. There has been no early treatment studies to date.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., Jun 2024, preprint, 1 author.
